Literature DB >> 12100042

Toll-like receptors: their role in allergy and non-allergic inflammatory disease.

I Sabroe1, L C Parker, A G Wilson, M K B Whyte, S K Dower.   

Abstract

The human TLRs comprise an important and interesting group of receptors that regulate pathogen-related responses, and play as yet uncharacterized roles in the amplication of sterile inflammation. Signalling through these receptors, which are powerfully coupled in gene transcription processes, has powerful immunostimulatory and immunomodulatory effects. Exploitation of TLR signalling will probably lead to novel effective therapies for allergic disease, in the first instance through more efficient mechanisms of immunotherapy. The likelihood of adverse consequences of such treatments, though possible, may be minimized by use of conjugated vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100042     DOI: 10.1046/j.1365-2745.2002.01451.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  23 in total

1.  Bacterial DNA induces pulmonary damage via TLR-9 through cross-talk with neutrophils.

Authors:  Kiyoshi Itagaki; Yasaman Adibnia; Shiqin Sun; Cong Zhao; Tolga Sursal; Yu Chen; Wolfgang Junger; Carl J Hauser
Journal:  Shock       Date:  2011-12       Impact factor: 3.454

Review 2.  Structural insights into the assembly of large oligomeric signalosomes in the Toll-like receptor-interleukin-1 receptor superfamily.

Authors:  Ryan Ferrao; Jixi Li; Elisa Bergamin; Hao Wu
Journal:  Sci Signal       Date:  2012-05-29       Impact factor: 8.192

3.  MLN4924 suppresses lipopolysaccharide-induced proinflammatory cytokine production in neutrophils in a dose-dependent manner.

Authors:  Jiayang Jin; Zhaofei Jing; Zhenjie Ye; Lu Guo; Lei Hua; Qingyang Wang; Jing Wang; Qianqian Cheng; Jiyan Zhang; Yunlu Xu; Lin Wei
Journal:  Oncol Lett       Date:  2018-03-23       Impact factor: 2.967

4.  Effect of stored product mite extracts on human dermal microvascular endothelial cells.

Authors:  B Laurel Elder; Marjorie S Morgan; Larry G Arlian
Journal:  J Med Entomol       Date:  2012-11       Impact factor: 2.278

5.  Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.

Authors:  Bahareh Kashani; Zahra Zandi; Mohammad Reza Karimzadeh; Davood Bashash; Ali Nasrollahzadeh; Seyed H Ghaffari
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

6.  Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment.

Authors:  Denise Richardt-Pargmann; Miriam Wechsler; Arthur M Krieg; Jörg Vollmer; Marion Jurk
Journal:  Immunobiology       Date:  2010-04-09       Impact factor: 3.144

7.  Inhibition of IRAK1 Ubiquitination Determines Glucocorticoid Sensitivity for TLR9-Induced Inflammation in Macrophages.

Authors:  Fansheng Kong; Zhiwei Liu; Viral G Jain; Kenjiro Shima; Takuji Suzuki; Louis J Muglia; Daniel T Starczynowski; Chandrashekhar Pasare; Sandip Bhattacharyya
Journal:  J Immunol       Date:  2017-10-16       Impact factor: 5.422

8.  Mycobacterium tuberculosis triggers apoptosis in peripheral neutrophils involving toll-like receptor 2 and p38 mitogen protein kinase in tuberculosis patients.

Authors:  Mercedes Alemán; Pablo Schierloh; Silvia S de la Barrera; Rosa M Musella; María A Saab; Matías Baldini; Eduardo Abbate; María C Sasiain
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

9.  Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.

Authors:  Angelo Corti; Monica Giovannini; Carmen Belli; Eugenio Villa
Journal:  J Oncol       Date:  2010-06-03       Impact factor: 4.375

10.  The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis.

Authors:  A H Montes; Victor Asensi; Victoria Alvarez; Eulalia Valle; M G Ocaña; A Meana; J A Carton; Jose Paz; J Fierer; A Celada
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.